Mark Sumeray
Director/Board Member chez Metys Pharmaceuticals AG
Profil
Mark Sumeray is currently a Director at Metys Pharmaceuticals AG.
Previously, he worked as the Chief Medical Officer at Aegerion Pharmaceuticals, Inc. from 2011 to 2016 and at Amryt Pharma Holdings Ltd.
from 2016 to 2022.
Dr. Sumeray received his undergraduate and doctorate degrees from University College London.
Postes actifs de Mark Sumeray
| Sociétés | Poste | Début |
|---|---|---|
Metys Pharmaceuticals AG
 Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The private company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | Director/Board Member | - |
Anciens postes connus de Mark Sumeray
| Sociétés | Poste | Fin |
|---|---|---|
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 27/06/2022 |
| AEGERION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 28/01/2016 |
Formation de Mark Sumeray
| University College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Metys Pharmaceuticals AG
Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The private company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | Health Technology |
